Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • COVID-19
    • COVID-19 Update
    • Evaluate Vantage COVID-19 Report
    • COVID-19 Stories from Evaluate Vantage
    • Evaluate’s Business Continuity Plan
  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Evaluate Custom Solutions
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Data Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Medtech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
    • Careers
      • Current Vacancies
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Data Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Corporate Relations

Thumbnail
July 24, 2018

More change needed to make US pricing truce permanent

Drug price inflation has slowed to crawl, but political pressure can only keep a lid on costs for so long.

Thumbnail
June 26, 2018

GE finally spins out Healthcare

GE arrives to the spin-out party fashionably late.

Article image
Vantage logo
May 14, 2018

How biopharma is meeting the next payer challenge

With their higher costs co-pay accumulators could be a step backwards for reducing patients' drug price burden.

Vantage logo
May 01, 2018

Bye, Repatha – price cut on Praluent wins exclusive Express Scripts deal

Vantage logo
March 08, 2018

Cigna writes the postscript on the age of the pharmacy benefit manager

Article image
Vantage logo
March 06, 2018

As US hospitals consolidate their pharmacy muscles grow

Consolidation of hospital chains could give biopharma another powerful group of payers to contend with.

Vantage logo
December 14, 2017

Tax reform means more cash for big pharma – albeit with an up-front fee

Vantage logo
November 08, 2017

Ask booksellers what Amazon might mean for medicines

Vantage logo
August 25, 2017

Snippet roundup: Adamas and Alexion score approvals and Amgen gets the price right

Vantage logo
June 27, 2017

Vantage Point – CAR-T value calculation in the firing line

Article image
Vantage logo
April 11, 2017

Calling time on biotech’s shady stock-promotion schemes

The US regulator has come down surprisingly hard on biotech stock promotion schemes.

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

February 11, 2021

Evaluate Vantage Pharma, Biotech & Medtech 2020 in Review

December 10, 2020

Evaluate Vantage 2021 Preview

View more...

Editor's Picks

Vantage logo
February 10, 2021

2020 wins top of the froths for biotech stocks

Vantage logo
October 04, 2018

Biotech flotations remain in high demand

Vantage logo
February 04, 2021

Glaxo’s growth problem

Vantage logo
January 27, 2021

Go or no go? Oncology decisions ahead for the FDA

Vantage logo
February 05, 2021

Pfizer reveals its PD-1 secret

Open modal

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-(0)80-1164-4754

Footer menu

  • Terms and Conditions
  • Privacy Policies
  • Cookie Policy

© Copyright 2021 Evaluate Ltd.